Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$53.10 USD

53.10
4,689,021

+1.90 (3.71%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

by Neena Mishra

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

by Sweta Killa

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research

by Zacks Equity Research

Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.

Kinjel Shah headshot

Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

by Kinjel Shah

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

Week Begins with Biotech Mergers

by Zacks Equity Research

Week Begins with Biotech Mergers

Mark Vickery headshot

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

by Mark Vickery

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

by Zacks Equity Research

Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.

Regeneron Reports Positive Data on Rare Blood Disorder Drug

by Zacks Equity Research

Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.

Alnylam Gets Second Product Approval Amid Stiff Competition

by Zacks Equity Research

Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.

Esperion's Promising Drugs Under Review, Funds a Concern

by Zacks Equity Research

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.

Novartis (NVS) to Acquire The Medicines Company for $9.7B

by Zacks Equity Research

Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

Amarin's Shares Down on Underperform Rating by Oppenheimer

by Zacks Equity Research

Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.

Protalix Finalizes Accelerated Approval Pathway for PRX-102

by Zacks Equity Research

Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's

Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

by Zacks Equity Research

Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.

Mark Vickery headshot

Top Stock Reports for Chevron, HSBC & Sanofi

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), HSBC Holdings (HSBC) and Sanofi (SNY).

Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

by Zacks Equity Research

GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

by Zacks Equity Research

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

by Kinjel Shah

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

by Zacks Equity Research

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength

by Zacks Equity Research

Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

by Kinjel Shah

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales

by Zacks Equity Research

Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.